Irsa Inversiones Y Rep S A (IRS) Holder Tricadia Capital Management Trimmed Stake; Artal Group Sa Has Trimmed Its Stake in Array Biopharma (ARRY) by $1.50 Million

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Tricadia Capital Management Llc decreased its stake in Irsa Inversiones Y Rep S A (IRS) by 20.99% based on its latest 2018Q3 regulatory filing with the SEC. Tricadia Capital Management Llc sold 94,712 shares as the company’s stock declined 8.56% with the market. The hedge fund held 356,508 shares of the homebuilding company at the end of 2018Q3, valued at $6.04 million, down from 451,220 at the end of the previous reported quarter. Tricadia Capital Management Llc who had been investing in Irsa Inversiones Y Rep S A for a number of months, seems to be less bullish one the $834.84M market cap company. The stock decreased 2.43% or $0.36 during the last trading session, reaching $14.47. About 6,932 shares traded. IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) has declined 53.85% since February 13, 2018 and is downtrending. It has underperformed by 53.85% the S&P500.

Artal Group Sa decreased its stake in Array Biopharma Inc (ARRY) by 5% based on its latest 2018Q3 regulatory filing with the SEC. Artal Group Sa sold 100,000 shares as the company’s stock rose 7.15% while stock markets declined. The institutional investor held 1.90 million shares of the major pharmaceuticals company at the end of 2018Q3, valued at $28.88 million, down from 2.00M at the end of the previous reported quarter. Artal Group Sa who had been investing in Array Biopharma Inc for a number of months, seems to be less bullish one the $4.66B market cap company. The stock decreased 0.19% or $0.04 during the last trading session, reaching $21.33. About 2.66M shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 42.87% since February 13, 2018 and is uptrending. It has outperformed by 42.87% the S&P500. Some Historical ARRY News: 06/03/2018 – Bristol-Myers: Opdivo Dosing Now Includes 480 Mg Infused Every Four Weeks for Majority of Approved Indications; 23/05/2018 – Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line; 16/04/2018 – OPDIVO 1-YEAR PROGRESSION-FREE SURVIVAL RATE `SUPERIOR BENEFIT’; 08/03/2018 – REG-Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 06/03/2018 – Bristol-Myers Opdivo Indicated for Metastatic Melanoma, Other Cancers; 13/04/2018 – OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCE…; 06/03/2018 – Bristol-Myers: FDA Approves Supplemental Biologics License Application Updating Opdivo Dosing Schedul; 06/04/2018 – Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma; 08/05/2018 – ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA; 13/04/2018 – BMY: OPDIVO SHOWED STAT SIG BENEFIT VERSUS DOCETAXEL

Since August 15, 2018, it had 1 insider buy, and 13 sales for $19.86 million activity. Shares for $3.93 million were sold by Squarer Ron on Wednesday, January 30. COX CARRIE SMITH had bought 3,000 shares worth $50,595. VAN LUNSEN GIL J had sold 21,500 shares worth $299,280. Robbins Andrew R sold 239,626 shares worth $4.80M. Another trade for 14,029 shares valued at $252,523 was sold by Oltmans Curtis Gale. On Wednesday, February 6 LEFKOFF KYLE sold $721,074 worth of Array BioPharma Inc. (NASDAQ:ARRY) or 35,000 shares.

Artal Group Sa, which manages about $3.84B US Long portfolio, upped its stake in Audentes Therapeutics Inc by 14,000 shares to 250,000 shares, valued at $9.90M in 2018Q3, according to the filing. It also increased its holding in Tesaro Inc (Call) (NASDAQ:TSRO) by 150,000 shares in the quarter, for a total of 500,000 shares, and has risen its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO).

More notable recent Array BioPharma Inc. (NASDAQ:ARRY) news were published by: Seekingalpha.com which released: “SSYS, ARRY among premarket gainers – Seeking Alpha” on January 15, 2019, also Seekingalpha.com with their article: “Array BioPharma Inc. 2019 Q1 – Results – Earnings Call Slides – Seeking Alpha” published on October 30, 2018, Seekingalpha.com published: “Two To Trade? MiMedX And Array – Seeking Alpha” on August 25, 2017. More interesting news about Array BioPharma Inc. (NASDAQ:ARRY) were released by: Profitconfidential.com and their article: “ARRY Stock Is Now Primed for a Move Toward Higher Prices – Profit Confidential” published on May 14, 2018 as well as Nasdaq.com‘s news article titled: “Key FDA Events in June Investors Need to Watch Out For – Nasdaq” with publication date: June 01, 2018.

Among 12 analysts covering Array BioPharma (NASDAQ:ARRY), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Array BioPharma had 45 analyst reports since June 3, 2016 according to SRatingsIntel. The company was maintained on Wednesday, August 9 by Stifel Nicolaus. The company was downgraded on Friday, February 3 by JP Morgan. The firm has “Buy” rating by Piper Jaffray given on Wednesday, May 31. As per Tuesday, October 31, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, February 6. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Friday, June 3 by Suntrust Robinson. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given on Friday, February 3 by Stifel Nicolaus. Cowen & Co maintained the shares of ARRY in report on Sunday, September 10 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Thursday, May 10. Stifel Nicolaus maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Sunday, January 21. Stifel Nicolaus has “Buy” rating and $20.0 target.

Investors sentiment decreased to 0.91 in Q3 2018. Its down 0.21, from 1.12 in 2018Q2. It worsened, as 28 investors sold ARRY shares while 59 reduced holdings. 22 funds opened positions while 57 raised stakes. 194.80 million shares or 2.17% more from 190.66 million shares in 2018Q2 were reported. Rech Mngmt Company accumulated 100 shares or 0% of the stock. Alkeon Capital Management Lc reported 0.16% stake. 27.10 million were accumulated by Fmr Ltd. State Street holds 0.01% in Array BioPharma Inc. (NASDAQ:ARRY) or 8.93 million shares. Citadel Advsr Limited Liability Company holds 0% in Array BioPharma Inc. (NASDAQ:ARRY) or 320,572 shares. Sphera Funds Mngmt Ltd holds 395,000 shares. Hollencrest Capital Mngmt has 100,000 shares. Shell Asset Mgmt Communication accumulated 20,581 shares. Royal Bancshares Of Canada stated it has 0% in Array BioPharma Inc. (NASDAQ:ARRY). 3,991 were accumulated by Fincl Bank Of Montreal Can. Livingston Grp Inc Asset Mngmt (Operating As Southport Management) invested in 500 shares. Citigroup has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Mutual Of America Capital Mgmt Limited Company has 145,928 shares for 0.03% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 13,779 shares. Kennedy Management Incorporated holds 722,543 shares.

More notable recent IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) news were published by: Globenewswire.com which released: “Crown Castle Announces Tax Reporting Information for 2018 Distributions – GlobeNewswire” on January 24, 2019, also Globenewswire.com with their article: “Mueller Water Products Reports 2019 First Quarter Results – GlobeNewswire” published on February 04, 2019, Seekingalpha.com published: “Getting It Right – Significant Underestimation Of Income – Seeking Alpha” on August 06, 2018. More interesting news about IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:IRS) were released by: Seekingalpha.com and their article: “Mercury General Corporation (MCY) CEO Gabriel Tirador on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on February 11, 2019 as well as Prnewswire.com‘s news article titled: “IRSA Inversiones y Representaciones SA announces that it has filed its 20-F Form for FY 2018 ended June 30, 2018 – PR Newswire” with publication date: November 01, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart